NeurRx Medical utilizes catheter-based techniques to deliver targeted interventions for ischemic stroke and deep vein thrombosis, restoring blood flow in obstructed vessels. The company aims to reduce long-term disability and enhance recovery outcomes for patients suffering from these vascular conditions.
Funding
$256K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Ischemic stroke and deep vein thrombosis (DVT) require rapid intervention to restore blood flow and prevent long-term complications. Current thrombectomy technologies for these conditions can be inefficient, sometimes requiring multiple passes and potentially leading to distal embolization.
Solution
NeurRx Medical develops percutaneous thrombectomy technologies designed to improve the speed and efficacy of clot removal in patients with ischemic stroke and DVT. Their devices enable endovascular specialists to achieve rapid clot stabilization, retention, and retrieval under image guidance. The company's focus is on addressing unmet needs in existing thrombectomy systems, including the removal of adherent clot, to simplify procedures and improve patient outcomes. By improving the efficiency of thrombectomy, NeurRx Medical aims to reduce the risk of permanent disability, venous ulceration, and limb loss associated with these vascular conditions.
Target Audience
The primary users are endovascular specialists treating patients with ischemic stroke and deep vein thrombosis.
Features
- Percutaneous thrombectomy devices for ischemic stroke and DVT
- Technology focuses on rapid clot stabilization and retention
- Image-guided clot retrieval
- Designed to address unmet needs of current thrombectomy systems
- Facilitates removal of adherent clot